Research programme: metabolic disorder therapeutics - reMYND

Drug Profile

Research programme: metabolic disorder therapeutics - reMYND

Alternative Names: ReS13-I; ReS39; ReS39-I

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator reMYND
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Non-alcoholic steatohepatitis

Most Recent Events

  • 14 Dec 2017 reMYND and Novo Nordisk enter into license agreement for the development of ReS39
  • 21 Jul 2016 Preclinical trials in Diabetes mellitus in Belgium (reMYND pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top